. Author manuscript; available in PMC: 2020 Aug 5.

Published in final edited form as: Clin Cancer Res. 2019 May 29;25(16):4973–4984. doi: 10.1158/1078-0432.CCR-19-0197

Table 2.

Contingency table comparing KRAS ctDNA detection during postpancreatectomy follow-up to clinical disease recurrence

	No disease recurrence	Disease recurrence	Total
KRAS ctDNA negative during follow-up	14 (11, 23, 26, 27, 44, 47, 51, 66, 68, 72, 77, 78, 84, 87)	3 (60, 85, 86)	17 (37%)
KRAS ctDNA borderline during follow-up	2 (61, 88)	5 (19, 22, 74, 81, 83)	7 (15%)
KRAS ctDNA positive during follow-up	0 ()	22 (5, 10, 15 20, 25, 29, 32, 34, 35, 38, 40, 41, 46, 59, 63, 64, 65, 75, 79, 89, 90, 91)	22 (48%)
Total	16 (35%)	30 (65%)	46 (100%)

NOTE: Individual patient numbers displayed in brackets.